MicroRNA-548 Regulates High Mobility Group Box 1 Expression in Patients With Preterm Birth and Chorioamnionitis by 김영한
1Scientific RepoRtS |         (2019) 9:19746  | https://doi.org/10.1038/s41598-019-56327-9
www.nature.com/scientificreports
MicroRNA-548 regulates high 
mobility group box 1 expression 
in patients with preterm birth and 
chorioamnionitis
Ga-Hyun Son  1,2,3,6, Youngmi Kim3,6, Jae Jun Lee3,4, Keun-Young Lee1, Heejin Ham1,  
Ji-Eun Song1, Sung Taek park  1,3* & Young-Han Kim2,5*
High mobility group box 1 (HMGB1) is a prototypic alarmin and plays an important role in the 
pathogenesis of inflammatory process in spontaneous preterm birth. This study was conducted 
to compare the levels of HMGB1 in amniotic fluid and amnion membranes in women with 
chorioamnionitis/intra-amniotic inflammation to the levels in healthy controls. We also aimed to 
elucidate the involvement of microRNA-548 (miR-548) in regulating HMGB1 expression and its function 
in human amniotic epithelial cells (hAECs). A bioinformatics analysis predicted the binding of HMGB1 
by the miR-548 cluster. A repressed and forced expression assay in hAECs was performed to investigate 
the causal relationship between the miR-548 cluster and HMGB1. The levels of HMGB1 in amniotic 
fluid and amnion membranes were significantly higher in patients with intra-amniotic inflammation/
chorioamnionitis than in those without inflammation. The miR-548 was significantly under-expressed 
in amnion membranes from patients with chorioamnionitis than in normal term controls. Repressed 
expression of miR-548 up-regulated HMGB1 expression in hAECs and increased its release from hAECs. 
Moreover, forced expression of miR-548 suppressed HMGB1 and inflammatory cytokines in hAECs, 
which increased when treated with lipopolysaccharide. These results suggest miR-548 can alter the 
inflammatory responses in hAECs, and might be involved in the pathogenesis of preterm birth by 
regulating HMGB1.
During pregnancy, fetal chorioamniotic membranes are involved in a variety of physiological and patho-
logical processes, such as accommodation and protection of the developing fetus, parturition, and response 
to intra-amniotic infections1. Infections and inflammations of the amniotic cavity are often accompanied by 
histologic chorioamnionitis, which is associated with both preterm delivery and adverse perinatal outcome2. 
Intra-amniotic inflammation (IAI) can be due to microbial invasion of the amniotic cavity or other mechanisms 
in which necrosis or cellular stress induces the release of mediators that activate the innate immune system3–5. 
Damage associated molecular patterns (DAMPs), including S100 calcium binding protein B (S100B)6, heat shock 
proteins7, interleukin (IL)-1α7–9, and high mobility group box 1 protein (HMGB1)10,11, are endogenous proinflam-
matory and pro-oxidative stress molecules that can induce the inflammatory process in patients without demon-
strable infection (sterile inflammation)7,10,11. Acting through Toll-like receptor 2 and 4 (TLR2 and TLR4), and 
by the receptor for advanced glycation end products (RAGE), DAMPs recruit inflammatory cells, which in turn 
amplify the innate immune response, thus favoring cytokine activation12. It was reported that the RAGE-DAMP 
system is present in women with preterm birth and IAI. Activation of the RAGE-DAMP system correlates with 
the degree of inflammation and oxidative stress damage in amnion epithelial, decidual, and extravillous troph-
oblast cells13. In addition, many infectious and inflammatory diseases, particularly in early childhood, have a 
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strong genetic predisposition. A substantial body of evidence has shown that there is genetic susceptibility in the 
duration of gestation and the risk of preterm birth14–18. Inherited differences in immune system genes influence 
the susceptibility to microbial infection, which is a well-known cause of acute chorioamnionitis19–21.
HMGB1 is a prototypic alarmin that has a central role in the pathogenesis of both sterile and infectious 
inflammation22–29. Elevated concentrations of HMGB1 may reflect engagement of DAMP-induced inflamma-
tion26,27,29–31. Although primarily located in the cell nucleus, HMGB1 can be secreted by innate immune cells 
in response to pathogenic products and can be released by injured or dying cells32. Buhimschi et al. reported 
that HMGB1 levels are increased in the amniotic fluid (AF) of women with IAI and preterm birth. Through 
explant experiments, the authors also showed that intra-amniotic HMGB1 might be released from the damaged 
amniochorion33. Additionally, intra-amniotic administration of HMGB1 was reported to induce spontaneous 
preterm labor and birth34. These findings suggested that intra-amniotic HMGB1 secreted from fetal membranes 
can induce premature labor and, therefore, may be involved in signaling parturition in the context of sterile 
intra-amniotic inflammation. The amnion is the innermost layer of the intra-amniotic cavity. Thus, we can pos-
tulate that the amnion, rather than the chorion, plays a major role in response to changes in the amniotic cavity, 
such as IAI35. However, little is known about the role of amnion in preterm birth determined by IAI.
MicroRNAs (miRNAs) are a class of non-coding small RNAs ranging from 18 to 25 nucleotides in size, which 
are involved in post-transcriptional regulation of gene expression by mRNA degradation or translational repres-
sion. The repression results from miRNA binding to the complementary sequence of the 3ʹ-untranslated region 
(3ʹUTR) of the target mRNA36. The roles of miRNAs are profound in various physiologic and pathologic pro-
cesses, such as cellular growth, development, organogenesis, and apoptosis37. MiRNAs have been implicated in 
various disease states that include cancer and cardiovascular diseases, and are considered important therapeutic 
targets. In addition, miRNAs are involved in most types of inflammatory responses, and there is increasing evi-
dence that miRNAs are effective in regulating the magnitude of inflammatory responses through their effects on 
cellular development and acute cellular function38. Despite the growing importance of miRNAs in pathogenic 
states, few studies have explored the role of miRNAs in IAI and their possible involvement in preterm birth. A 
recent microarray analysis compared the miRNAomes in plasma between patients with spontaneous preterm 
birth and those with delivery at term. A total of eight miRNAs were differentially expressed in preterm birth 
groups, and miR-302b, miR-1253, and a cluster of miR-548 miRNAs were significantly under-expressed in pre-
term birth cases compared to term controls39. However, the potential role of these miRNAs in preterm birth 
remains unknown.
Of the differentially expressed miRNAs in preterm birth groups, the miR-548 cluster and miR-302b were 
predicted to bind HMGB1 3′UTR by a bioinformatics analysis. Thus, we performed this study to (1) compare 
the levels of HMGB1 in amniotic fluid of patients with intra-amniotic inflammation to those in healthy controls, 
(2) compare HMGB1 expression in amnion membrane of patients with preterm birth and chorioamnionitis to 
normal term controls, and (3) investigate the expression of the miR-548 cluster in amnion membrane and explore 
the regulation of HMGB1 expression by the miR-548 cluster.
Results
HMGB1 expression in AF and amnion membrane. We analyzed HMGB1 levels in AF obtained from 
women with signs or symptoms of preterm birth who had amniocentesis to rule out infection (n = 38) or for 
either genetic indication (n = 10). Table 1 shows a comparison of clinical characteristics of patients with amnio-
centesis. Thirty four of 48 patients were diagnosed with IAI. The median [interquartile range] AF concentration 
of HMGB1 was significantly higher in patients with IAI than in those without IAI (563.8 [373.0–800.0] vs 273.0 
[47.0–539.3] pg/mL, p = 0.004; Fig. 1A). The levels of HMGB1 significantly correlated with the levels of IL-6 
(r = 0.571; p < 0.001; Fig. 1C).
The expressions of HMGB1 mRNA and protein were increased in amnion membranes from women with 
preterm birth and acute chorioamnionitis as compared to normal controls (Fig. 2A). To confirm these data, 
we measured the expression level of HMGB1 in primary human amnion epithelial cells (hAECs) isolated from 
amnion membrane obtained from patients who delivered preterm due to acute chorioamnionitis (patient-derived 
hAECs, PD-hAECs) and women who had full-term pregnancy as normal control (hAECs). As expected, HMGB1 
expression in PD-hAECs was significantly higher than in hAECs (Fig. 2B). Additionally, HMGB1 release from 
PD-hAECs was highly augmented compared to hAECs (Fig. 2C). These date implicated HMGB1 as a novel can-
didate biomarker for the early prediction of preterm birth determined by chorioamnionitis.
MiR-548 cluster is under-expressed in amnion membrane from patients with preterm birth 
and acute chorioamnionitis. Several miRNAs, including the miR-548 cluster, are reportedly downregu-
lated in spontaneous preterm birth cases compared to controls39. Thus, we investigated the correlation between 
HMGB1 and the miR-548 cluster. Several binding sites of the miR-548 cluster were computationally predicted in 
the 3′UTR of HMGB1 (Table 2). To explore whether the miR-548 cluster could be a negative regulator of HMGB1 
in preterm birth with acute chorioamnionitis, the expression level of the miR-548 cluster, including miR-548aa, 
miR-548ai, miR-548-3p, and miR-548x-5p, was measured using qPCR in the amnion membrane. Also, we inves-
tigated miR-302b, which displays reduced expression in spontaneous preterm birth39. As shown in Fig. 3A, all 
members of the miR-548 cluster were significantly decreased in amnion membranes from preterm women with 
acute chorioamnionitis compared to those from normal term controls. Furthermore, the expression of the miR-
548 cluster was reduced in PD-hAECs than in hAECs from normal healthy women (Fig. 3B). However, there 
was no significant difference in the expression level of miR-302b between preterm and normal controls (data not 
shown). These results suggested that miR-548 cluster could be an inhibitory regulator of HMGB1 expression in 
preterm birth with acute chorioamnionitis.
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MiR-548 cluster can regulate expression of HMGB1 in hAECs. To validate the correlation between 
HMGB1 and the miR-548 cluster in patients with preterm birth and acute chorioamnionitis, we investigated 
whether the expression level of the miR-548 cluster is crucial to the HMGB1 expression level using the synthetic 
mimics and inhibitors for the miR-548 cluster (Table 3) in hAECs. To examine whether the downregulation of 
miR-548 cluster could induce the enhancement of HMGB1 expression, hAECs were transfected with miR-548aa 
inhibitor, miR-548ai inhibitor, miR-548a-3p inhibitor, or miR-548x-5p inhibitor followed by qPCR (Fig. 4A). 
Inhibitors of the miR-548 cluster obviously increased the expression of both mRNA and protein levels of HMGB1 
in hAECs compared to control inhibitor (Fig. 4B). Moreover, HMGB1 levels increased in the culture medium of 
hAECs transfected with miR-548 inhibitor compared to those transfected with control inhibitor (Fig. 4C). These 
findings indicated that downregulation of the miR-548 cluster contributed to the overexpression of HMGB1 
expression in preterm birth with acute chorioamnionitis. In addition, the negative correlation between the 
expression of the miR-548 cluster and HMGB1 level was implicated in preterm birth with acute chorioamnionitis.
Lipopolysaccharide-induced inflammation induces enhanced HMGB1 expression through 
downregulation of miR-548 cluster. To evaluate the role of the negative correlation between the miR-
548 cluster and HMGB1 in preterm birth with acute chorioamnionitis, hAECs were treated with lipopolysaccha-
ride (LPS) (10 or 100 ng/mL) for 24 h to induce inflammation followed by measurement of the expression levels 
of the miR-548 cluster and HMGB1. Compared to control, LPS inhibited the expression of the miR-548aa and 
miR-548ai and led to increases of HMGB1 mRNA and protein in hAECs (Fig. 5A,B). A significant elevation of 
HMGB1 levels was also observed in the culture medium of LPS-stimulated hACEs as compared to normal con-
trol medium (Fig. 5C). These findings indicated that downregulation of the miR-548 cluster promoted HMGB1 
expression in hAECs and its subsequent release from the cells upon LPS-mediated inflammation.
MiR-548 cluster can attenuate LPS-induced inflammation in hAECs. To verify the effect of the 
miR-548 cluster on LPS-induced expression and release of HMGB1, hAECs were transfected with miR-548aa 
mimic, miR-548ai mimic, miR-548a-3p mimic, miR-548x-5p mimic, or control mimic. HMGB1 mRNA and pro-
tein expressions were pronounced in hAECs transfected with control mimic stimulated by LPS. In contrast, over-
expression of the miR-548 cluster in cells transfected with miR-548 cluster mimics lowered HMGB1 induction 
upon LPS exposure (Fig. 6A). Moreover, HMGB1 levels were decreased in the culture medium of the miR-548 
mimic transfected hAECs as compared to control mimic cells (Fig. 6B). Those findings indicated that the miR-548 
mimic inhibited HMGB1 up-regulation in hAECs and the subsequent release of HMGB1 from hAECs exposed 
to an inflammatory stimulus. Furthermore, release of inflammatory cytokines (IL-1ß and IL-6) and chemok-
ine (IL-8) was significantly reduced in the culture medium of hAECs transfected with miR-548 cluster mimics 
compared to control mimic cells. The data indicated that the overexpression of miR-548 cluster can suppress the 
inflammatory responses in hAECs.
Discussion
This study demonstrates that the HMGB1 levels in AF from the patients with IAI were significantly higher than 
from those without IAI, and that HMGB1 was highly expressed in amnion membranes of patients with preterm 
birth and acute chorioamnionitis as compared to those in normal term controls. In addition, we validated that 
LPS-mediated inflammation could be responsible of the observed HMGB1 up-regulation in hAECs and for the 
release of HMGB1 from hAECs in vitro. Our findings, confirmed both in vivo and in vitro, were consistent with 
the fact the inflammation induced the expression of HMGB1 in the amnion membrane and its release from the 
amnion epithelial cells. HMGB1 is actively released by stimulation of the innate immune system with exogenous 
pathogen-derived molecules. Neurons, astrocytes, erythroleukemia cells, neuroblastoma cells, and other tumor 
cells are also reportedly able to actively secrete HMGB112,27–29,40. Passive release of HMGB1 can be initiated when 
cellular integrity is damaged32. Considering that HMGB1 expression in hAECs increased when the cells were 
stimulated by LPS, HMGB1 could be released actively from amnion epithelial cells. Moreover, inflammation of 
Patients with IAI 
(n = 34)
Normal controls 
(n = 14) p-value
Maternal age (years) 33 [30.8–36.0] 36.5 [33.8–38.5] 0.005
Previous preterm delivery 5 (14.7) 1 (7.1) 0.656
Gestational age at amniocentesis (weeks) 21.0 [19.6–22.4] 17.4 [16.7–19.9] <0.001
Gestational age at delivery (weeks) 29.4 [21.0–38.0] 38.0 [37.0–38.5] 0.002
Maternal WBC count (cell/mL) 9,750 [8,375–12,350] 8,885 [7,395–11,012] 0.353
Amniotic fluid analysis
HMGB1 (pg/mL) 563.8 [373.0–800.0] 273.0 [47.0–539.3] 0.004
IL-6 (pg/mL) 6,022 [5,199–6,224] 588 [465–1,175] <0.001
Glucose < 20 mg/dL, n (%) 10 (29.4) 0 0.023
WBC (cells/mm3) 40 [7.0–137.5] 7.0 [2.0–9.3] 0.019
Positive cultures 2 (5.9) 0 1.000
Table 1. Clinical characteristics of patients with amniocentesis. Data presented as median [interquartile range] 
or n (%). IAI, intra-amniotic inflammation; WBC, white blood cell; HMGB1, High mobility group box 1; IL-6, 
interleukin-6.
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the amnion membrane might lead to injury of amnion epithelial cells, which might cause the passive release of 
HMGB1. Regardless of the mechanism, the elevated levels of HMGB1 in AF could be considered a marker for 
amnion epithelial cell damage and injury, and representative of active signal transduction in amnion epithelial 
cells. It remains unclear how the released HMGB1 affects the amnion epithelial cells and plays a role in leading 
to preterm birth. We speculate that HMGB1 might induce cytokine, chemokine, and metalloproteinase synthesis 
that might be involved in preterm birth.
Little is known about the involvement of the miR-548 family in disease processes. Downstream targets of the 
miR-548 family are involved in breast cancer, inflammatory responses, and potential estrogen receptor sensi-
tivity, indicating a potential biological role in the setting of preterm birth41–43. A recent study reported the sup-
pression of endogenous miR-548 levels in the setting of viral infections42. Similarly, we observed that significant 
Figure 1. Levels of HMGB1 and IL-6 in amniotic fluid. (A,B) Levels of HMGB1 and IL-6 in amniotic fluid of 
women with and without intra-amniotic inflammation. (C) Relationship of amniotic fluid HMGB1 to the acute 
phase cytokine interleukin (IL)-6.
Figure 2. HMGB1 mRNA and protein expression in amnion membrane and human amniotic epithelial cells 
(hAECs). (A) HMGB1 mRNA and protein expression in the amnion membrane from women with preterm 
birth and chorioamnionitis and from normal term controls. (B) HMGB1 mRNA and protein expression in 
hAECs from patients with preterm birth and chorioamnionitis and from normal term controls. (C) HMGB1 
levels in culture medium of hAECs from patients with preterm birth and chorioamnionitis and from normal 
term controls. **Significant difference (P < 0.001) compared with control group. hAECs, human amniotic 
epithelial cells; PD-hAECs, patient-derived human amniotic epithelial cells.
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suppression of the miR-548 cluster was observed in the amnion membrane from patients with preterm birth 
and acute chorioamnionitis compared to normal term controls. Moreover, when hAECs were treated with LPS, 
miR-548 was downregulated. A previous study reported that inflammation does alter miRNAs at intestinal epi-
thelial barriers and regulates intestinal permeability by degradation of tight junction protein, which is the target 
protein of miRNAs44. Furthermore, in cervical cells, inflammation can significantly alter the expression of specific 
miRNAs; these alterations might be involved in cervical remodeling and preterm birth45. Although the mecha-
nism of miR-548 downregulation following inflammatory stimuli has not been clarified, our results suggest that 
under-expressed miR-548 can play an important role in acute chorioamnionitis determined preterm birth.
This study demonstrates that LPS downregulated the expression of the miR-548 in hAECs, and the inhibition 
of miR-548 induced the up-regulation of HMGB1 mRNA and protein expression, and release of HMGB1 in 
the culture medium of hAECs transfected with miR-548 cluster inhibitors. These findings suggest that IAI can 
induce downregulation of the miR-548 in the amnion membrane, thus leading to the up-regulated expression 
of HMGB1 in amnion and its release from amnion epithelial cells. Moreover, the miR-548 cluster mimic could 
reverse the LPS-induced up-regulation of HMGB1 in hAECs compared to control mimic. The release of HMGB1 
from hAECs was also significantly decreased in hAECs transfected with miR-548 cluster mimics. In addition, the 
release of inflammatory cytokines and chemokine was suppressed in the culture medium of hAECs transfected 
with miR-548 cluster mimics compared to control mimic cells. These findings suggest that miR-548 cluster mim-
ics can inhibit the up-regulation of HMGB1 that occurs when inflammation is stimulated, and alters inflamma-
tory responses in hAECs. Thus, we can speculate that miR-548 could effectively reverse and prevent the activation 
of innate immunity, and significantly attenuate damage in IAI.
A key strength of this study is our demonstration that amniotic epithelial cells can release HMGB1. HMGB1 
is increased in the AF of women with preterm birth and IAI. Further, increased AF HMGB1 can cause preterm 
birth. However, the source of AF HMGB1 had not been determined. Our findings identified the important role 
of the amnion membrane in preterm birth by releasing HMGB1 and other proinflammatory cytokines during 
IAI. In addition, we elucidated that there is a microRNA/target protein network involved in preterm birth with 
IAI/chorioamnionitis. A few studies have reported that there are miRNAs differentially expressed in women with 
preterm birth; however, little is known about the role of miRNAs in preterm birth and how their involvement 
may induce preterm birth. We have demonstrated that inflammation can alter miR-548 expression in the amnion 
membrane and suppression of miR-548 can enhance inflammatory responses in the AF, leading to preterm birth.
ID Alignment Position
miR-548aa
target (5′ → 3′)
miRNA (3′ → 5′) 1298–1305
target (5′ → 3′)
miRNA (3′ → 5′) 1681–1686
target (5′ → 3′)
miRNA (3′ → 5′) 1499–1504
miR-548ai target (5′ → 3′)miRNA (3′ → 5′) 1591–1596
miR-548a-3p
target (5′ → 3′)
miRNA (3′ → 5′) 306–311
target (5′ → 3′)
miRNA (3′ → 5′) 2376–2381
target (5′ → 3′)
miRNA (3′ → 5′) 2024–2030
miR-548x-5p
target (5′ → 3′)
miRNA (3′ → 5′) 523–529
target (5′ → 3′)
miRNA (3′ → 5′) 516–523
target (5′ → 3′)
miRNA (3′ → 5′) 869–874
Table 2. Predicted sequence alignment between miRNAs and HMGB1 3′UTR.
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One limitation of this study is that we did not demonstrate direct binding of the miR-548 cluster to HMGB1. 
However, the bioinformatics data and our forced and repressed experiment adequately showed the relationship 
between miR-548 and HMGB1. In addition, we could not clearly determine whether a change in the amount 
Figure 3. MicroRNA-548 cluster expression in amnion membrane and human amniotic epithelial cells 
(hAECs). (A) Levels of miRNA-548aa, miRNA-548ai, miRNA-548a-3p, and miRNA-548x-5p in amnion 
membranes from women with preterm birth and chorioamnionitis and from normal term controls. (B) Levels 
of miRNA-548aa, miRNA-548ai, miRNA-548a-3p, and miRNA-548x-5p in patient-derived hAECs (PD-hAECs) 
and hAECs from normal healthy women. **Significant difference (P < 0.01) compared with control group, 
*Significant difference (P < 0.05) compared with control group. hAECs, human amniotic epithelial cells.























Table 3. Sequences of miR-mimic, miR-inhibitor, and controls.
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of proinflammatory cytokines and chemokines secreted during LPS treatment was directly caused by altered 
miRNA expression or secondary to the secretion of HMGB1. Moreover, the gestational age of obtaining amniotic 
fluid and amnion could not be matched between the patient and control groups. Therefore, the difference in 
HMGB1 concentration between the patient and control groups may have been affected by differences in gesta-
tional age. Although, one previous study has reported no significant difference in the median AF HMGB1 con-
centration between women in the mid-trimester and those at term not in labor11, further studies are required to 
examine the HMGB1 concentration in AF and amnion membrane throughout pregnancy.
In conclusion, intra-amniotic inflammation induces the up-regulation of HMGB1 expression in the amnion 
membrane and HMGB1 release via suppression of miR-548. Moreover, miR-548 can attenuate inflammatory 
responses in amnion epithelial cells. Although the specific regulatory mechanism of miR-548 on HMGB1 expres-
sion remains unclear, these data demonstrate a potential molecular mechanism underlying the inhibitory effect 
of miR-548 on preterm birth, and implicate miR-548 as a potential therapeutic target in preterm birth with 
chorioamnionitis.
Methods
Patients and amniotic fluid collection. We investigated AF samples from 48 women with singleton 
pregnancies and clinically indicated amniocentesis. Samples were obtained by transabdominal amniocentesis 
for second trimester genetic karyotyping (n = 10) or to rule out AF infection in women who had preterm labor 
contractions refractory to tocolysis or advanced cervical dilatation (n = 38). Exclusion criteria were the presence 
of anhydramnios, human immunodeficiency or hepatitis viral infections, congenital anomalies, or abnormal kar-
yotype. Gestational age was determined based on the last menstrual period confirmed by ultrasound examination 
Figure 4. MicroRNA-548 cluster can regulate expression of HMBG1 in human amniotic epithelial cells 
(hAECs). (A) Levels of miRNA-548aa, miRNA-548ai, miRNA-548a-3p, and miRNA-548x-5p in hAECs 
transfected with miRNA-548aa inhibitor, miRNA-548ai inhibitor, miRNA-548a-3p inhibitor, miRNA-548x-5p 
inhibitor, and control inhibitor. (B) HMGB1 mRNA and protein expression in hAECs transfected with miRNA-
548 inhibitor and with control inhibitor. (C) HMGB1 levels in culture medium of hAECs transfected with 
miRNA-548 inhibitor and with control inhibitor. **Significant difference (P < 0.01) compared with control 
group. hAECs, human amniotic epithelial cells.
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prior to 14 weeks gestation. Preterm labor was defined as the presence of regular uterine contractions and docu-
mented cervical effacement and/or dilatation in patients before week 37 of gestation. IAI was defined by amniotic 
fluid interleukin (IL)-6 concentrations ≥2,600 pg/mL46. All women provided written informed consent before the 
collection of AF and placenta samples. The collection and utilization of the samples were approved by the Ethics 
Committee of Kangnam Sacred Heart Hospital (Ethics ref.: 2017-08-014). All experiments were performed in 
accordance with the relevant guidelines and regulations.
Chemical and microbiological studies of AF. Following retrieval under sterile conditions, AF was ana-
lyzed for glucose concentration, white blood cell (WBC) count, gram stain, and for standard culture of aerobic 
and anaerobic bacteria, including Ureaplasma and Mycoplasma species. The remaining AF was aliquoted into 
2-mL vials and cryopreserved at −80 °C.
Enzyme-linked immunosorbent assay (ELISA) of AF HMGB1 and IL-6. The levels of IL-6 and 
HMGB1 in AF and cell culture medium (conditioned medium) were determined by an ELISA assay kit (Cusabio, 
Wuhan, China) according to the manufacturer’s instructions. The levels of IL-1ß and IL-8 in culture medium were 
determined by an ELISA assay kit (Cusabio and RayBiotech, Norcross, GA, USA, respectively) according to the 
manufacturer’s instructions.
Amnion collection and processing. Placentas (n = 6) were obtained from women with suspected chori-
oamnionitis caused by prolonged latency after preterm premature rupture of membranes and/or preterm labor 
(median gestational age of 29.4 weeks, range 25.3–35.0 weeks), and from healthy women (n = 4) undergoing 
elective cesarean delivery at term in the absence of labor (median gestational age 38.1 weeks, range 20.1–39.0 
weeks). Amnion membrane was manually stripped from the chorion and divided into small pieces (approxi-
mately 1.0 cm3 each). After sample collection, the remaining full-thickness placental biopsies were obtained and 
fixed in formalin. Biopsy specimens were interpreted by a placental pathologist who was blinded to the clinical 
and laboratory findings. Amnion samples histologically diagnosed with acute chorioamnionitis were used as 
patients’ samples in the experiments.
Figure 5. Lipopolysaccharide (LPS)-mediated inflammation induces enhanced HMGB1 expression through 
downregulation of microRNA-548 cluster. (A) Levels of miRNA-548aa, miRNA-548ai, miRNA-548a-3p, 
and miRNA-548x-5p in hAECs treated with 10 or 100 ng/mL LPS for 24 h. (B) HMGB1 mRNA and protein 
expression in hAECs treated with 10 or 100 ng/mL LPS for 24 h. (C) HMGB1 levels in culture medium of 
hAECs treated with 10 or 100 ng/mL LPS for 24 h. **Significant difference (P < 0.01) compared with control 
group, hAECs, human amniotic epithelial cells; LPS, Lipopolysaccharide.
9Scientific RepoRtS |         (2019) 9:19746  | https://doi.org/10.1038/s41598-019-56327-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Isolation of amniotic epithelial cells. Amnion membranes (n = 5, median gestational age 38.3 weeks, 
range 37.4–39.0 weeks) were obtained from women who had completed full-term pregnancy during elective 
cesarean deliveries before the onset of labor and from those (n = 5, median gestational age 23.3 weeks, range 
18.3–34.5 weeks) with preterm birth and acute chorioamnionitis. The primary hAECs were isolated from freshly 
obtained amnion as described previously47–50. Briefly, the amnion membrane was washed with ice-cold phosphate 
buffered saline (PBS, pH 7.2) to remove blood clots and cellular debris, and cut into pieces approximately 6 cm 
long. The first enzymatic digestion was performed by incubating the membrane pieces with 20 mL of pre-warmed 
0.05% trypsin/EDTA (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C for 10 min with gentle shaking. The 
cells obtained at this step were discarded to remove blood clots and cellular debris. Second and third digestions 
were conducted the same way. The membrane pieces were transferred into new 50-mL conical tubes contain-
ing 20 mL 0.05% trypsin/EDTA and incubated at 37 °C for 30 min with gentle shaking. The digestion mixtures 
obtained from the second and third digestions were filtered through a 70-μm cell strainer and centrifuged at 
500 × g for 10 min. Cell pellets were suspended and grown in DMEM/F12 (Gibco, Franklin Lakes, NJ, USA) sup-
plemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin (Sigma-Aldrich, St. Louis, 
MO, USA), and 10 ng/mL epidermal growth factor (R&D Systems, Madison, WI, USA).
Cell culture and reagents. The primary hAECs from amnion tissues were plated and maintained in culture 
at 37 °C in a humidified incubator in an atmosphere of 5% CO2. JetPrime transfection reagent was purchased 
from PolyPlus-Transfection (Strasbourg, France). Antibodies to HMGB1 (Cell Signaling Technology, Beverly, 
MA, USA) and Actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. LPS from Escherichia coli 
strain 0111:B4 was obtained from Sigma-Aldrich.
Western blot analysis. Western blot analysis was performed according to standard procedures51. Equal 
amounts of proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to polyvinylidene fluoride membranes (Thermo Fisher Scientific). Target proteins 
were detected by enhanced chemiluminescence reagents (Thermo Fisher Scientific).
Figure 6. MicroRNA-548 cluster can attenuate lipopolysaccharide (LPS)-induced inflammation in hAECs. 
(A) HMGB1 mRNA and protein expression in miRNA-548 mimic and control mimic transfected hAECs that 
were not treated or treated with LPS. (B) HMGB1 levels in culture medium of miRNA-548 mimic and control 
mimic transfected hAECs that were not treated or treated with LPS. (C) IL-1β, IL-6, and IL-8 levels in culture 
medium of miRNA-548 mimic and control mimic transfected hAECs that were not treated or treated with LPS. 
**Significant difference (P < 0.001) compared with control mimic group, *Significant difference (P < 0.001) 
compared with control group. hAECs, human amniotic epithelial cells; LPS, Lipopolysaccharide; IL, interleukin.
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MicroRNA prediction of target genes and functional and bioinformatics analysis. Binding 
sites and sequences of miR-548 cluster on the HMGB1 3′UTR were predicted by the target prediction programs 
TargetScan (http://www.targetscan.org), MiRDB (http://mirdb.org), and miRmap (https://mirmap.ezlab.org). 
Paired sequence alignment is marked by red color and continuous lines (Table 2).
RNA isolation and quantitative PCR (qPCR). Total RNA samples were isolated from cells and amnion 
tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Five micrograms of RNA was used for cDNA syn-
thesis using the Maxime RT PreMix Kit (iNtRON Biotechnology, Seoul, South Korea). PCR reactions were per-
formed using a 2× Rotor-Gene SYBR Green PCR Master Mix (Qiagen, Carlsbad, CA, USA) in the Rotor-Gene Q 
(Qiagen). The primers used were HMGB1 (forward): 5′-ACATCCAAAATCTTGATCAGTTA-3′ and (reverse) -3′ 
(reverse) 5′-CTCCTTAATGTC ACGCACGA-3′; and Actin (forward): 5′-CATGTACGTTGCTA TCCAGGC-3′ 
(reverse) 5′-CTCCTTAATGTCACGCACGA-3′. For the analysis of miRNA expression, miRNAs were isolated 
from the hAECs and amnion tissues using miRNeasy (Qiagen), followed by reverse transcription with the miS-
cript Transcription Kit (Qiagen). The miRNA expression level was measured with a miScript SYBR Green PCR 
Kit (Qiagen) using the Rotor-Gene Q (Qiagen). Primers for miRNAs and endogenous control U6 gene are shown 
in Table 4.
Forced and repressed expression of miRNA-548 cluster. To verify the effect of miRNAs, miR-548 
inhibitor, mimic, and negative control groups were transfected using JetPrime (Polyplus-Transfection). Total 
RNA, including miRNA and proteins, were isolated at 36 h post-transfection and were used for western blot 
analysis and qPCR. The sequences of miR-inhibitor and mimic are listed in Table 2. hAECs were incubated in the 
presence of 10 and 100 ng/mL LPS to induce inflammation. Culture medium was collected after 24 h of incubation 
to measure the levels of HMGB1.
Statistical analyses. All experiments were repeated at least three separate times. Statistical analyses were 
performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Data were compared with Student’s t test for 
parametric data or Mann-Whitney U test for nonparametric data. The Kruskal-Wallis test with Bonferroni cor-
rections was used for multiple comparisons. Spearman correlations were used to measure co-linearity between 
the selected independent variables. Comparisons between proportions were done with Fisher’s exact test. 
Statistical analysis of the immunoassays data was performed after logarithmic transformation of data. Statistical 
significance was indicated when p < 0.05.
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